BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems to Host Third Quarter 2026 Earnings Call

Delcath Systems (DCTH)Delcath SystemsEarnings

QUEENSBURY, N.Y. --(BUSINESS WIRE)--Oct. 26, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 9, 2026, at 8:30 AM Eastern Time to

Related news

ICUIICU Medical2026-10-22 12:30 EST

ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call

EHCEncompass Health Corporation2026-10-01 20:30 EST

Encompass Health announces date of 2026 third-quarter earnings call

LEGNLegend Biotech Corporation2026-10-27 12:00 EST

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

SNDXSyndax Pharmaceuticals2026-10-26 11:00 EST

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

SHCSotera Health2026-10-21 11:00 EST

Sotera Health Announces Third-Quarter 2026 Earnings Release Date

ACHCAcadia Healthcare2026-10-13 13:00 EST

Acadia Healthcare Announces Date for Third Quarter 2026 Earnings Release

LMATLeMaitre Vascular2026-10-12 20:49 EST

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026

IARTIntegra LifeSciences2026-10-06 12:30 EST

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

View all latest news

Delcath Systems

Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure. HEPZATO KIT HEPZATO KIT combines melphalan with the company's percutaneous...

Recent company news

DCTHDelcath Systems2026-10-27 12:30 EST

Delcath Systems to Participate in Upcoming Investor Conferences

DCTHDelcath Systems2026-10-26 12:30 EST

Delcath Systems to Host Third Quarter 2026 Earnings Call

DCTHDelcath Systems2026-10-19 20:01 EST

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

DCTHDelcath Systems2026-09-11 20:01 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DCTHDelcath Systems2026-08-31 20:01 EST

Delcath Systems to Participate in Upcoming Investor Conferences

Stock data

Close
14.49 USD
Market cap
363.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States